Welcome to the ADIS project

ADIS stands for “Early Diagnosis of Alzheimer’s Disease by Immune Profiling of Cytotoxic Lymphocytes and Recording of Sleep Disturbances”. The research project brings together EU-leading expertise in data science, biotechnology, clinical research as well as public involvement.

As the title already highlights, the partners aim to advance research into one of the most challenging conditions, Alzheimer’s disease.

Our mission is to strive for earlier diagnosis of Alzheimer’s disease.

Latest news

17
May

Partners from Fraunhofer SCAI present ADIS at “14. Bonner Wissenschaftsnacht” to the public

On 16 and 17 May partners from Fraunhofer SCAI presented the ADIS (and COMMUTE) project...
Read More
23
Apr

New publication: Towards early diagnosis of Alzheimer’s disease: advances in immune-related blood biomarkers and computational approaches

Alzheimer’s disease has an increasing prevalence in the population world-wide, yet current diagnostic methods based...
Read More
14
Mar

Welcome to the second issue of the ADIS newsletter!

The ADIS project is dedicated to advancing early diagnosis of Alzheimer’s disease through immune profiling...
Read More
28
Feb

The ADIS Advisory Board meets online to discuss the terminology of a brain health campaign for young adults

On 27 February, members of the ADIS Advisory Board gathered online. The meeting was also...
Read More

Subscribe to our newsletter


 
  • Prof. Dr. Holger Fröhlich
    Fraunhofer Institute for Algorithms and Scientific Computing (SCAI)

    ADIS will leverage cutting edge science and technology in conjunction with long lasting clinical expertise to provide candidate biomarkers for earlier diagnosis of Alzheimer’s disease. An earlier diagnosis means that treatments slowing down symptom worsening would have higher success chance in the future and that patients could better plan their life. I am very enthusiastic about the motivation and energy of the entire consortium to reach our ambitious goals and really looking forward to the upcoming three years of working together.

  • José Antonio García García
    Member of the ADIS Advisory Board

    Contributing with our experience to research is essential to obtain better results for a better and longer quality of life for people with Alzheimer’s disease and their carers or supporters.

    Research does not advance without us and we do not advance without research.

  • Kina
    Member of the ADIS Advisory Board

    I think it is vital to contribute to research with our lived experience so that we can raise awareness, be part of the solution that may benefit us and others in the future, and fight the stigma around Alzheimer’s disease.

  • Soraya Moradi-Bachiller
    Public Involvement Officer Alzheimer Europe

    Combining research with the lived experience of people with Alzheimer’s disease is the only way forward to make significant progress from which people who have this disease, or will have it in the future, will benefit.